Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
SRPT [NASD]
Sarepta Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.39 Insider Own0.50% Shs Outstand37.77M Perf Week5.08%
Market Cap921.59M Forward P/E- EPS next Y-3.38 Insider Trans- Shs Float34.47M Perf Month-14.89%
Income-112.00M PEG- EPS next Q-0.78 Inst Own73.30% Short Float37.40% Perf Quarter-12.86%
Sales14.20M P/S64.90 EPS this Y35.60% Inst Trans0.79% Short Ratio9.70 Perf Half Y-48.33%
Book/sh6.57 P/B3.71 EPS next Y-2.10% ROA-46.00% Target Price25.50 Perf Year-27.70%
Cash/sh6.80 P/C3.59 EPS next 5Y20.00% ROE-66.80% 52W Range12.12 - 55.61 Perf YTD19.78%
Dividend- P/FCF- EPS past 5Y-9.80% ROI-36.30% 52W High-56.12% Beta0.86
Dividend %- Quick Ratio7.50 Sales past 5Y-7.80% Gross Margin- 52W Low101.32% ATR1.82
Employees146 Current Ratio7.50 Sales Q/Q-64.40% Oper. Margin- RSI (14)48.84 Volatility7.69% 8.10%
OptionableYes Debt/Eq0.01 EPS Q/Q90.30% Profit Margin- Rel Volume0.75 Prev Close24.23
ShortableYes LT Debt/Eq0.01 EarningsMay 05 Payout- Avg Volume1.33M Price24.40
Recom2.70 SMA200.50% SMA50-7.32% SMA200-20.93% Volume1,001,324 Change0.70%
04-Mar-14Reiterated Canaccord Genuity Hold $25 → $27
21-Jan-14Upgrade Needham Hold → Buy $36
26-Nov-13Upgrade WBB Securities Sell → Speculative Buy $9 → $19
13-Nov-13Downgrade Needham Buy → Hold
13-Nov-13Downgrade Deutsche Bank Buy → Hold $71 → $17
12-Nov-13Reiterated FBR Capital Mkt Perform $48 → $20
30-Oct-13Initiated FBR Capital Mkt Perform $48
06-Sep-13Initiated Stifel Buy $51
22-Apr-13Initiated Needham Buy $57
04-Apr-13Initiated Robert W. Baird Outperform $63
03-Apr-13Initiated Robert W. Baird Outperform $63
08-Mar-13Reiterated Burrill Institutional Research Mkt Outperform $54 → $39
26-Nov-12Initiated Burrill Institutional Research Mkt Outperform $54
12-Sep-12Downgrade WBB Securities Hold → Sell $8 → $9
09-Aug-12Initiated WBB Securities Hold $8
09-Aug-12Downgrade WBB Securities Speculative Buy → Hold
15-Apr-14 09:41AM  Why Investors Need to Watch Sarepta Therapeutics Inc. at Motley Fool
08-Apr-14 02:34PM  Sarepta Therapeutics on Cusp of Huge Eteplirsen News at TheStreet
07-Apr-14 05:43PM  [video] Biotech breakdown? at CNBC +7.29%
02-Apr-14 07:59AM  Top Gainers Technical Data -- Research on BGC Partners, Sarepta Therapeutics, TripAdvisor, and LiveDeal PR Newswire
01-Apr-14 02:41AM  Why Now Is The Time To Get Behind Sarepta Therapeutics at Seeking Alpha +6.99%
26-Mar-14 03:22PM  UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Investors of Class Action Against SAREPTA THERAPEUTICS, INC. and Its Board of Directors and a Lead Plaintiff Deadline of March 28, 2014 Business Wire
08:30AM  Sarepta Therapeutics to Present Company Overview at the 2014 Needham Healthcare Conference Business Wire
22-Mar-14 07:25AM  SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Sarepta Therapeutics, Inc. to Contact Brower Piven Before the March 28, 2014 Lead Plaintiff Deadline (SRPT) GlobeNewswire
19-Mar-14 04:33PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against SAREPTA THERAPEUTICS, INC. and Its Board of Directors and a Lead Plaintiff Deadline of March 28, 2014 Business Wire
18-Mar-14 12:50PM  Prosensa Muscular Dystrophy Data Send Stock Rising at Investor's Business Daily
11:03AM  Prosensa Making the Best of Inconsistent Drisapersen Data at TheStreet
08:21AM  Prosensa jumps 30% after data from Phase 2 study of DMD drug at theflyonthewall.com
14-Mar-14 03:14PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline -- SRPT GlobeNewswire
03:14PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline -- SRPT
02:32PM  What Lies Ahead For Sarepta Therapeutics, Inc.? at Motley Fool
02:32PM  What Lies Ahead For Sarepta Therapeutics, Inc.?
12-Mar-14 05:42PM  [video] Biotech can't go up forever: Pro Optionetics +6.76%
05:42PM  [video] Biotech can't go up forever: Pro at CNBC
05:42PM  [video] Biotech can't go up forever: Pro
02:10PM  Chimerix climbs after FDA agrees to allow pilot trial of brincidofovir at theflyonthewall.com
02:10PM  Chimerix climbs after FDA agrees to allow pilot trial of brincidofovir
08-Mar-14 01:04PM  SAREPTA THERAPEUTICS, INC. Financials EDGAR Online Financials
01:04PM  SAREPTA THERAPEUTICS, INC. Financials
07-Mar-14 06:49PM  SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Sarepta Therapeutics, Inc. to Contact Brower Piven Before the March 28, 2014 Lead Plaintiff Deadline -- SRPT GlobeNewswire
06:49PM  SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Sarepta Therapeutics, Inc. to Contact Brower Piven Before the March 28, 2014 Lead Plaintiff Deadline -- SRPT
06:17PM  The Nasdaq's 5 Most Hated Stocks at Motley Fool
04-Mar-14 06:32PM  Why Sarepta Therapeutics Inc. Might Have a Fighting Chance at Motley Fool
06:32PM  Why Sarepta Therapeutics Inc. Might Have a Fighting Chance
06:29PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against SAREPTA THERAPEUTICS, INC. and Its Board of Directors and a Lead Plaintiff Deadline of March 28, 2014 -- SRPT PR Newswire
09:57AM  On Sarepta's 2013 Results And Upcoming Events at Seeking Alpha
09:57AM  On Sarepta's 2013 Results And Upcoming Events
03-Mar-14 04:59PM  SAREPTA THERAPEUTICS, INC. Files SEC form 10-K, Annual Report EDGAR Online
01:21PM  Sarepta Therapeutics: Tale of a Biotech Rollercoaster at Motley Fool
28-Feb-14 03:02PM  SHAREHOLDER ALERT: Pomerantz Law Firm has filed a Class Action Against Sarepta Therapeutics, Inc. and Certain Officers - SRPT PR Newswire
27-Feb-14 04:13PM  Sarepta Therapeutics' CEO Discusses Q4 2013 Results - Earnings Call Transcript at Seeking Alpha
12:46PM  Sarepta price target raised to $34 from $21 at Stifel at theflyonthewall.com
12:15PM  Sarepta Therapeutics Q4 Loss More Than Triples on a Doubling in Expenses at Motley Fool
08:00AM  Sarepta Therapeutics Inc Earnings Call scheduled for 8:00 am ET today CCBN
07:17AM  Sarepta sees FY14 loss from operations $110M-$120M at theflyonthewall.com
07:08AM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an EDGAR Online
07:07AM  Q4 2013 Sarepta Therapeutics Inc Earnings Release - Before Market Open CCBN
07:00AM  Sarepta Therapeutics Announces Fourth Quarter and Full Year 2013 Financial Results and Recent Corporate Developments Business Wire
26-Feb-14 05:52AM  Sarepta (SRPT) Enters Overbought Territory Zacks
25-Feb-14 01:05PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against SAREPTA THERAPEUTICS, INC. and Its Board of Directors and a Lead Plaintiff Deadline of March 28, 2014 -- SRPT GlobeNewswire
24-Feb-14 10:39AM  The 10 Most Heavily Shorted Bio-Pharma Stocks at TheStreet +7.63%
05:14AM  Trades are optimistic on Sarepta optionMONSTER
21-Feb-14 10:00AM  Chen Lin's Perfect Biotech Market Prescription: Buy Low, Sell High at Seeking Alpha
20-Feb-14 04:05PM  Sarepta Therapeutics to Present Company Overview at the Cowen and Company 34th Annual Healthcare Conference Business Wire
12:01AM  JPMorgan Dad Turns Biotech CEO in Quest to Save His Son Bloomberg
12:01AM  JPMorgan Dad Starts Biotech in Muscular Dystrophy Quest at Bloomberg
17-Feb-14 03:37PM  3 Biotech Stocks to Avoid: Amarin, Dendreon, and Prosensa at Motley Fool
14-Feb-14 05:11PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline -- SRPT GlobeNewswire
13-Feb-14 08:30AM  Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2013 Financial Results and Corporate Update on February 27, 2014 Business Wire
10-Feb-14 08:30AM  Sarepta Therapeutics Announces Positive Safety Results from Phase I Clinical Study of Marburg Drug Candidate Business Wire
07-Feb-14 02:05PM  Do Away With The Pill-A-Day Biotech Model: Steve Brozak at Seeking Alpha +5.12%
06-Feb-14 01:16PM  Advocates set to meet with Congress on Sarepta DMD drug at theflyonthewall.com
05-Feb-14 02:03PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Sarepta Therapeutics, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of March 28, 2014 -- SRPT Marketwired +9.45%
02:03PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Sarepta Therapeutics, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of March 28, 2014 -- SRPT Marketwire
08:30AM  Sarepta Therapeutics Announces Eteplirsen Demonstrates Stability on Pulmonary Function Tests through 120 Weeks in Phase IIb Study in Duchenne Muscular Dystrophy Business Wire
04-Feb-14 06:32PM  Companies Limp Towards a Duchenne Treatment Is There Hope of a Finish Line? at Motley Fool
05:59PM  Attention Sarepta Therapeutics, Inc. Investors: Sarepta Misled Investors According to a Recently Filed Class Action PR Newswire
31-Jan-14 05:41PM  Morgan & Morgan Announces That a Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. -- SRPT GlobeNewswire
05:41PM  Morgan & Morgan Announces That a Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. -- SRPT
30-Jan-14 03:42PM  SHAREHOLDER ALERT: Pomerantz Law Firm Has Filed a Class Action Against Sarepta Therapeutics, Inc. and Certain Officers -- SRPT GlobeNewswire
03:42PM  SHAREHOLDER ALERT: Pomerantz Law Firm Has Filed a Class Action Against Sarepta Therapeutics, Inc. and Certain Officers -- SRPT
02:39PM  Wolf Haldenstein Announces Investigation of Sarepta Therapeutics, Inc., Business Wire
02:39PM  Wolf Haldenstein Announces Investigation of Sarepta Therapeutics, Inc.,
28-Jan-14 03:30PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against SAREPTA THERAPEUTICS, INC. and Its Board of Directors and a Lead Plaintiff Deadline of March 28, 2014 -- SRPT GlobeNewswire
03:30PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against SAREPTA THERAPEUTICS, INC. and Its Board of Directors and a Lead Plaintiff Deadline of March 28, 2014 -- SRPT
27-Jan-14 06:19PM  INVESTOR ALERT: Federman & Sherwood Files First Securities Class Action Lawsuit Against Sarepta Therapeutics, Inc. Marketwired
06:19PM  INVESTOR ALERT: Federman & Sherwood Files First Securities Class Action Lawsuit Against Sarepta Therapeutics, Inc. Marketwire
06:19PM  INVESTOR ALERT: Federman & Sherwood Files First Securities Class Action Lawsuit Against Sarepta Therapeutics, Inc.
06:24AM  Sarepta downgraded to Market Perform from Outperform at JMP Securities theflyonthewall.com
06:24AM  Sarepta downgraded to Market Perform from Outperform at JMP Securities
24-Jan-14 12:18AM  Intercept Pharmaceticals & Chelsea Therapeutics: Which is Best? at Motley Fool -7.69%
12:18AM  Intercept Pharmaceticals & Chelsea Therapeutics: Which is Best?
23-Jan-14 07:25AM  The Zacks Analyst Blog Highlights: Celgene, Jazz, Sarepta, Alnylam and Regeneron Zacks
07:25AM  The Zacks Analyst Blog Highlights: Celgene, Jazz, Sarepta, Alnylam and Regeneron
05:56AM  How Sarepta Trading Will Evolve at Seeking Alpha
05:56AM  How Sarepta Trading Will Evolve
22-Jan-14 12:48PM  Professional Investor Explains His 2 Largest Healthcare Holdings at Seeking Alpha
12:48PM  Professional Investor Explains His 2 Largest Healthcare Holdings
09:50AM  Professional Investor Explains His 2 Largest Healthcare Holdings at Seeking Alpha
21-Jan-14 01:16PM  The 3 Most Intriguing Stories From the JPMorgan Healthcare Conference at Motley Fool
07:55AM  Sarepta Therapeutics upgraded by Needham Briefing.com
07:55AM  Sarepta Therapeutics upgraded by Needham
07:23AM  Sarepta upgraded to Buy from Hold at Needham at theflyonthewall.com
07:23AM  Sarepta upgraded to Buy from Hold at Needham
18-Jan-14 07:54PM  JPMorgan Healthcare Conference Highlights: Sarepta Therapeutics at Motley Fool
07:54PM  JPMorgan Healthcare Conference Highlights: Sarepta Therapeutics
01:18PM  This Week in Biotech: Clinical Trials and Tribulations at Motley Fool
09:36AM  The Best- And Worst-Performing Biotech Stocks, Jan. 10 to Jan. 17 at Forbes
08:32AM  3 Humongous Health-Care Stocks This Week at Motley Fool
08:32AM  3 Humongous Health-Care Stocks This Week
17-Jan-14 01:50PM  My Five Favorite Bio-Pharma Stocks from the J.P. Morgan Healthcare Conference at TheStreet
01:50PM  My Five Favorite Bio-Pharma Stocks from the J.P. Morgan Healthcare Conference
01:42PM  A Big Day for Duchenne Muscular Dystrophy Drugmakers at Motley Fool
01:42PM  A Big Day for Duchenne Muscular Dystrophy Drugmakers
12:32AM  Sarepta Therapeutics (SRPT) Soars: Stock Up 40.1% Zacks
12:32AM  Sarepta Therapeutics (SRPT) Soars: Stock Up 40.1%
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. Its lead product candidate is Eteplirsen, an antisense PMO-based therapeutic in clinical development for the treatment of individuals with Duchenne muscular dystrophy. The company is also involved in developing treatments that are in clinical development include AVI-7288 for the treatment of Marburg virus and AVI-7100 for the treatment of influenza. In addition, it focuses on developing preclinical research product candidates for the treatment of other neuromuscular, infectious, and rare diseases. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.